PubMed Health⌕ Search

PubMed · 7711768

Ototoxicity in developing mammals.

Abstract

Developing mammals are more sensitive to noise, chemical and drug-induced ototoxicity than adults, with maximum sensitivity occurring during periods of anatomical and functional maturation of the cochlea. Normal physiological development of resting potentials (the endocochlear potential) and sound-evoked potentials including cochlear microphonics, summating potentials, compound action potentials, auditory brainstem responses and more recently distortion-product otoacoustic emissions have been characterized in several species including rats, mice, kittens, gerbils and guinea pigs. All of these responses are significantly impaired following acoustic trauma and/or exposure to a variety of ototoxic agents including aminoglycoside antibiotics, loop diuretics, antithyroid and antitumor drugs (alpha-difluoromethylornithine) and excitatory amino acids. Coupled with physiological and anatomical development is the maturation of specific biochemical pathways, which may be vulnerable targets of environmental noise and chemicals, excitatory amino acids and therapeutic drugs with ototoxic potentials.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C M Henley, L P Rybak. 1995. Ototoxicity in developing mammals.. https://doi.org/10.1016/0165-0173(94)00006-b

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Trends in cancer patient survival in Estonia before and after the transition from a Soviet republic to an open-market economy.

Cancer patients' survival is strongly dependent on socioeconomic factors, including access to and quality of medical care. During the past decade, Estonia has undergone a major political and economic change from a Soviet republic to an open-market economy country, and the health care system was transformed from a centralised state-controlled system into a decentralised health insurance-based one. Using data from the population-based Estonian Cancer Registry, we assessed trends in cancer patient survival before and after this transition by application of period analysis, a new method of survival analysis, which allows more timely disclosure of time trends than traditional survival analysis. Our study included 83,138 patients diagnosed with 1 of the 11 most frequent malignancies in Estonia from 1969-1998. Patients were followed up to the end of 1998. Despite a moderate increase in 5- and 10-year relative survival over time, prognosis for many common forms of cancer, such as stomach, colorectal, breast and ovarian cancer, remained considerably worse than the survival rates achieved in more affluent European countries many years ago. By contrast, a very steep increase in survival rates was observed for common urologic cancers, including prostate, kidney and bladder cancer, which went along with a rise in incidence rates of these cancers over time. For prostate cancer, similar survival rates as in other European countries have now been achieved. The most likely explanation for these trends is enhanced availability and utilization of laboratory and technical diagnostic equipment. Despite recent improvement, major efforts in delivering modern cancer care to the population of Estonia will be required to close the gap that continues to exist between prognosis of cancer patients in this country and other European countries.

Age Distribution↗

Getting older.

Explore the source record for details and available documents.

Age Distribution↗

Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years.

This population-based study was conducted in Veneto and Trentino (northwestern Italy, population 5 million). In this area, neonatal screening for cystic fibrosis started in 1973 and has been virtually universal since the early 1980s. During this study, the estimated incidence of cystic fibrosis in this region was 1/2,650 livebirths per year. The authors analyzed data on 593 patients born in 1938-2000 and living in the region who were followed by a single referral center. Median time from birth to confirmation of diagnosis after screening was 32 days (range, 0-1,531). For patients whose disease was recognized after symptoms occurred, median age at diagnosis was always less than 1 year. Median survival age was 37.7 years. Long-term survival (to age 20-30 years) was not significantly influenced by mode of diagnosis (screened or unscreened), sex, or age at diagnosis for unscreened patients (<1, 1-5, >5 years). Current survival analysis of three consecutive decades showed that improving survival tended to vanish in the last years of the study. The authors concluded that a regional neonatal screening program allows very early recognition of cystic fibrosis. They could not conclude that neonatal screening improves long-term survival if compared with diagnosis by symptoms in early infancy.

Age Distribution↗